Tempus AI, Inc. Common Stock (TEM.NASDAQ) AI FORECASTS & ADVISOR ANALYSIS

Read and compare the 12 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 12 August 2026Deep analysis 5 July 202625 min read

Audit All Past Forecasts

12 AI Advisor Reports

Select an advisor report.

Superintelligence AI

The Anthropologist FrameworkAI Thinker

Rating

Strong Buy

5-Year Return Est.

+266.3%

TEM.NASDAQ does not currently pay dividends

1. Investment Thesis — Base Case

The 'True Price' trajectory is a violent but upward grind, shaking out weak hands before fundamental compounding takes over. In the near term (Late 2026), TEM equity will suffer volatility as the Warsh Fed maintains elevated discount rates and the SpaceX/Anthropic mega-IPOs suck passive liquidity out of mid-cap AI names. However, by mid-2027, Tempus's 80%+ revenue growth and 70% gross margins will force an undeniable FCF inflection. The market cap of ~$10.8B is entirely realistic for a company positioned to be the terminal data operating system for the global biopharma industry, a sector deploying hundreds of billions in desperate R&D.

Near-term multiple compression driven by macro liquidity drain and rate gravity.
Mid-term margin explosion as proprietary data network effects mature.
Structural protection via BIOSECURE mandates driving domestic clinical data centralization.
Eventual re-rating from 'speculative software' to 'biopharma infrastructure tollbooth'.
Implied terminal valuation requires dominating the clinical trial matching space, which is highly probable given their current asymptotic data advantage.

Interactive forecast chart

Figure: Five-year interactive consensus forecast for Tempus AI, Inc. Common Stock, including the advisor-disagreement range and benchmark comparison. Sign in, verify your email, and use the required subscription to explore the chart.

AI Advisor 1

Superintelligence

Rating: strong_buy
Forecasted compounded return: +266.3%
Forecast anchor: 60.27 USD on July 2, 2026

Most reasonable investment thesis

The 'True Price' trajectory is a violent but upward grind, shaking out weak hands before fundamental compounding takes over. In the near term (Late 2026), TEM equity will suffer volatility as the Warsh Fed maintains elevated discount rates and the SpaceX/Anthropic mega-IPOs suck passive liquidity out of mid-cap AI names. However, by mid-2027, Tempus's 80%+ revenue growth and 70% gross margins will force an undeniable FCF inflection. The market cap of ~$10.8B is entirely realistic for a company positioned to be the terminal data operating system for the global biopharma industry, a sector deploying hundreds of billions in desperate R&D. - Near-term multiple compression driven by macro liquidity drain and rate gravity. - Mid-term margin explosion as proprietary data network effects mature. - Structural protection via BIOSECURE mandates driving domestic clinical data centralization. - Eventual re-rating from 'speculative software' to 'biopharma infrastructure tollbooth'. - Implied terminal valuation requires dominating the clinical trial matching space, which is highly probable given their current asymptotic data advantage.

Bull case

The macro liquidity drain is shallow, and Big Pharma accelerates its AI-outsourcing timeline under severe pricing pressure. Tempus signs multiple exclusive sovereign/pharma partnerships, while an FDA CDx mandate cements its platform as standard-of-care. - Revenue growth sustains >50% CAGR through 2028. - Gross margins push past 80%, demonstrating pure software economics. - Rapid transition to massive GAAP profitability triggers inclusion in major indices. - Market capitalization expands toward $35B+ as it establishes a true biological data monopoly.

Bear case

The Warsh Fed holds rates higher-for-longer, severely punishing TEM's multiple before it achieves cash-flow independence. Simultaneously, open-source medical LLMs commoditize data structuring, erasing Tempus's edge. - Hospital budget freezes stall top-line growth. - API token costs from foundational model providers crush gross margins. - Forced to issue dilutive equity in a hostile tape to cover cash burn. - Stock becomes a 'zombie growth' value trap, languishing as tech capital concentrates entirely in mega-cap hyperscalers.

Sentiment and regime

Greed and fear sentiment: -0.4
Expected volatility regime: high_erratic
Convergence-cycle position: momentum

Broader narrative

Current crowd consensus: The crowd views Tempus as an overvalued, cash-burning biotech/software hybrid drifting dangerously on the fumes of 2024's AI bubble. Media and sell-side analysts obsess over the $303M trailing net loss and the hostile Warsh rate environment, anchoring their bias on the assumption that anything unprofitable will be crushed by 5% 30-year yields. They treat TEM as a discretionary SaaS play that will be cannibalized by generic foundational models or starved of liquidity by the incoming Anthropic/SpaceX mega-IPOs.
Alpha-gap assessment: The variant perception is purely physical and thermodynamic. The market fundamentally misunderstands the difference between silicon compute moats and biological data moats. GPT-5.5 cannot sequence a tumor. The alpha gap exists because the crowd prices Tempus's R&D spend as 'burning cash', whereas it is actually CapEx building an unassailable information topology node. With revenues up 83% and gross margins jumping from 55% to 70%, Tempus is a violently accelerating negentropy engine. The market is mispricing the inevitability of its operating leverage.
Convergence catalyst: The absolute crossover into Free Cash Flow (FCF) positivity. Once Tempus prints its first unadjusted FCF-positive quarter, the 'cash-burning' bear thesis mathematically detonates. Expect this within 3 to 5 quarters, signaled in advance by SG&A flattening while top-line sequential growth persists.
Macro-regime alignment: The macro regime is highly bifurcated for Tempus. The Warsh monetary regime (high rates, steep curve) is a severe mechanical headwind for its equity duration. However, the geopolitical regime (BIOSECURE Act, decoupling, domestic resilience) is a massive structural tailwind for its fundamental business. The business model runs with the wind; the stock currently fights it.

Primary drivers

Primary drivers supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Proprietary DATA Topology Centralization	While silicon-based AI is commoditizing via DeepSeek and open-source models, Tempus owns the proprietary, multi-modal clinical and genomic data that cannot be scraped from the internet. This creates a terminal information monopoly. As frontier models become agentic, they require deep, structured biological data to execute clinical reasoning. Tempus sits at the absolute center of this information chokepoint, extracting rent from every pharmaceutical and diagnostic node that needs real-world evidence. This is a structural moat that compounding capital cannot easily replicate.	Not available%	+65.0%
Thermodynamic Negentropy Inflection	The crowd whines about net losses while completely ignoring the physics of the income statement. Revenue exploded 83% YoY to $1.27B while gross margins violently expanded from 55% to 70%. This is the definition of a negentropy engine: the system is becoming radically more efficient at converting raw inputs into high-value outputs. As R&D and SG&A growth decelerates relative to top-line compounding, the operating leverage will aggressively drag this company across the free cash flow zero-line.	Not available%	+40.0%
BIG Pharma R&d Offloading	Legacy pharmaceutical companies are bloated entropy accelerators with failing internal R&D ROI. To survive the 'TrumpRx' pricing pressures and the patent cliff, they must externalize target discovery and clinical trial matching. Tempus operates as the outsourced cognitive engine for Big Pharma, using its algorithmic matching to salvage failing pipelines. This shifts Tempus's revenue base from speculative tech budgets to non-discretionary survival budgets of multi-billion-dollar incumbents.	Not available%	+30.0%
Biosecure ACT Enactment Beneficiary	The geopolitical decoupling from China-linked genomic and life-science service providers (like BGI) forces a massive re-shoring of genomic sequencing and clinical data processing. Tempus is uniquely positioned as the default domestic beneficiary of this civilizational immune response. US biopharma and federal research grants are structurally rotating capital away from Asian CDMOs/sequencers directly into Tempus's US-compliant, hardened infrastructure. This is non-discretionary compliance-driven revenue.	Not available%	+25.0%

Primary frictions

Primary frictions supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Warsh Regime Discount RATE Gravity	The Warsh-led Fed's 'privatization of QE' and higher-for-longer stagflationary regime acts as severe gravity for long-duration growth equities. Tempus is currently unprofitable on a GAAP basis. The brutal mathematics of a higher discount rate mechanically compresses the multiple the market is willing to pay for terminal cash flows, regardless of how beautiful the gross margin trajectory is. Until GAAP profitability is achieved, TEM equity will suffer periodic valuation haircuts.	Not available%	-25.0%
MEGA IPO Liquidity Vacuum	The imminent mega-IPOs of SpaceX, Anthropic, and OpenAI act as a black hole for public market risk capital. Passive index mechanics and active manager reallocations will force indiscriminate selling of mid-tier AI growth names to fund allocations in these apex predators. Tempus will suffer collateral damage in this liquidity drain, facing multiple compression simply because capital allocators need to clear balance sheet space for the new titans.	Not available%	-20.0%
Healthcare Sector Margin Squeeze	The 'TrumpRx' pricing accords and sweeping NIH/FDA efficiency cuts create a hostile capital environment for Tempus's ultimate end-customers: hospitals and drug developers. If the end nodes of this network are starved for capital via aggressive government cost-containment, their willingness to pay premium SaaS and data-licensing fees to Tempus will stall, extending the timeline to Tempus's ultimate cash-flow targets.	Not available%	-15.0%
Agentic API COST Inflation	As Tempus integrates deeper reasoning models (like Claude Opus 4.8 or GPT-5.5) into its clinical workflows, the token-economics shift heavily against the application layer. Adaptive thinking and long-context agentic loops burn massive computational budgets. If Tempus cannot perfectly pass these API infrastructure costs through to its pharmaceutical and hospital clients, its glorious 70% gross margins will face unexpected compression from the compute-layer oligopoly.	Not available%	-10.0%

Tail opportunities

Tail opportunities supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Exclusive BIG Pharma Sovereign Partnership	A top-3 global pharmaceutical giant recognizes that generic AI is insufficient for biological target discovery and enters an exclusive, multi-billion-dollar sovereign data partnership with Tempus. This would effectively lock competing pharma companies out of the premium data tier, triggering a frantic M&A arms race or forcing an immediate repricing of Tempus's data assets from 'subscription SaaS' to 'strategic national asset'.	25.0%	+55.0%
Breakthrough Algorithmic Diagnostic Mandate	The FDA mandates a Tempus algorithmic diagnostic (CDx) as the gold-standard prerequisite for prescribing a blockbuster oncology or obesity drug. This converts Tempus from a clinical tool into a regulatory tollbooth. Once biologically anchored into the standard of care with no legal substitute, Tempus's revenue becomes infinitely durable, instantly closing the alpha gap and commanding a 20x+ P/S multiple.	35.0%	+40.0%

Tail risks

Tail risks supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Catastrophic Hipaa/genomic DATA Breach	Iranian or Russian state-sponsored cyber syndicates, highly active in the 2026 macro environment, successfully exfiltrate millions of sequenced genomic profiles from Tempus's servers. Given the biological sensitivity of the data, the regulatory backlash would be existential, instantly freezing hospital data-sharing agreements and triggering billions in class-action liabilities.	12.0%	-60.0%
OPEN Source Clinical LLM Displacement	A well-funded consortium releases a heavily fine-tuned, open-weight clinical model capable of ingesting raw, unstructured hospital EMR data directly, bypassing Tempus's structuring moat. If hospitals can run local, free inference to structure their own data rather than paying Tempus, the network topology flattens, commoditizing Tempus's core value proposition.	18.0%	-45.0%

Step-by-step forecast path

Superintelligence forecast path for prediction task predrqst_batch_task__xrefsubjtskconf_4c364781-74f0-5515-a7f2-38e3686bcd45__sb6__20260705153202
Step	Forecast date	Step change	Projected value (USD)	Scenario rationale
1	October 2, 2026	-6.0%	56.65	Liquidity vacuum effect. Passive index flows rebalance to absorb the SpaceX and Anthropic mega-IPOs, draining capital from mid-cap AI growth equities. Warsh Fed hawkishness maintains high discount rates, mechanically pressuring TEM's un-profitable multiple despite solid core operations.
2	January 2, 2027	+12.0%	63.45	Q4 earnings demonstrate continued gross margin expansion (pushing mid-70s) and a shrinking net loss. Markets begin to look past the IPO indigestion and recognize the BIOSECURE tailwinds forcing US pharma to shift contracts toward Tempus.
3	April 2, 2027	+15.0%	72.97	A breakout quarter. Operating leverage becomes impossible to ignore as SG&A growth flattens while top-line revenue compounds. Early signals of approaching free cash flow break-even trigger short-covering and fundamental value buying.
4	July 2, 2027	-4.0%	70.05	Standard mid-year tech sector rotation and profit-taking. High-beta names suffer as macro data prints hot, reigniting fears of persistent stagflationary constraints on healthcare end-market budgets.
5	October 2, 2027	+18.0%	82.66	The convergence catalyst hits. Tempus crosses the free cash flow zero-line. The 'cash-burning' bear thesis dies instantly. Institutional capital that requires positive cash flow parameters floods the stock, driving massive multiple expansion.
6	January 2, 2028	+10.0%	90.93	Year-end validation of the business model. Major clinical trial matching agreements with Big Pharma are announced. The market begins to value TEM less as SaaS and more as an irreplaceable biopharma infrastructure tollbooth.
7	April 2, 2028	+8.0%	98.20	Steady compounding phase begins. Agentic AI workflows within the Tempus platform demonstrate concrete ROI for hospital networks, increasing net revenue retention (NRR) and locking in long-term enterprise contracts.
8	July 2, 2028	-5.0%	93.29	Macro friction. A broader market drawdown tied to a deceleration in aggregate AI hyperscaler capex briefly drags all AI-adjacent equities down in sympathy, ignoring Tempus's decoupled biological demand layer.
9	October 2, 2028	+14.0%	106.35	Resumption of uptrend as Q3 earnings prove Tempus is immune to the silicon capex cycle. Continued gross margin expansion toward 80% solidifies its thermodynamic efficiency profile. GAAP profitability comes into view.
10	January 2, 2029	+16.0%	123.37	FDA signaling on algorithmic diagnostic mandates. Speculation mounts regarding regulatory capture of the precision medicine workflow. Market prices in a massive terminal moat.
11	April 2, 2029	+7.0%	132.00	Execution quarter. Consistent, boring beats on top and bottom lines. Tempus formally initiates its first meaningful share repurchase program out of organically generated free cash flow.
12	July 2, 2029	-7.0%	122.76	Temporary headwind from API infrastructure pricing. Foundational model providers raise token costs for advanced reasoning workloads, briefly spooking the market regarding Tempus's long-term margin durability.
13	October 2, 2029	+11.0%	136.27	Margin fears are proven wrong as Tempus successfully passes compute costs to enterprise clients, demonstrating absolute pricing power. Information topology centrality is confirmed.
14	January 2, 2030	+15.0%	156.71	Massive top-line acceleration from international expansion (European integration compliant with new EU data sovereignty frameworks). The data network effects hit asymptotic velocity.
15	April 2, 2030	-4.0%	150.44	Minor mean reversion. The stock consolidates gains after a multi-quarter rip. Valuation looks temporarily stretched on a forward P/E basis, inviting standard cyclical shorts.
16	July 2, 2030	+9.0%	163.98	Index inclusion momentum. As GAAP profitability stabilizes at high scale, Tempus meets criteria for larger passive benchmarks, driving mechanical algorithmic buying.
17	October 2, 2030	+12.0%	183.66	A blockbuster therapeutic discovered via Tempus's dataset receives FDA approval, proving the holy grail of AI-driven drug discovery. Pharma scramble to license the platform.
18	January 2, 2031	+8.0%	198.35	Maturity phase compounding. Tempus operates as the undisputed backbone of personalized medicine. Growth decelerates to ~25% CAGR, but operating margins are massive and highly defensible.
19	April 2, 2031	+5.0%	208.27	Stable dividend or aggressive buyback announcements. The transition from high-beta frontier pioneer to blue-chip healthcare technology infrastructure is complete.
20	July 2, 2031	+6.0%	220.76	The asset sits safely at the apex of the healthcare information topology. The civilizational trajectory alignment (longevity extension + digitization) ensures persistent, predictable cash flows regardless of economic cycles.

Advisor and configuration

Advisor: superintelligence__the_anthropologist__google_gemini_3_1_pro__20260201_preview_release
Persona: Superintelligence
Archetype: The Anthropologist
Model: (February 01, 2026) Preview Release
Provider: Google
Mode: THINKER with High Reasoning and Standard Creativity
Task configuration: superintelligence__the_anthropologist__google_gemini_3_1_pro__20260201_preview_release__equity__json__extnd_invest_thesis_4q_alphassym__ts_num_desc__h5y_s3m__var1__thinker__standard_creativity_high_thinking__batch
Forecast horizon: 5 year
Forecast steps: 20 steps of 3 month
Assembly type: Balanced Assembly
Assembly name: superintelligence__the_anthropologist__google_gemini_3_1_pro__20260201_preview_release THINKER Forecast Assembly
Input format: Latest Close Price with Stats and Fundamentals
Output format: Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

Read the complete Superintelligence advisor methodology

Configuration components

aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa (subject_context)
aiassmprmtcmpnt_efec62e4-24c0-556a-8070-775c69b97643 (global_context)
aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa (subject_context)
aiassmprmtcmpnt_8115cc2a-d418-54b1-a616-49dfa91195f4 (task_guidelines)

Back to advisor navigation

Complete advisor preview locked

Unlock this report and every AI Advisor

Sign in to check your access, or upgrade to the Base plan to read this report and open every advisor.

Sign in to check access View Base plan Return to latest AI Consensus